Rezolute reports first quarter fiscal 2022 financial results and highlights recent company progress

Redwood city, calif., nov. 12, 2021 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first quarter of fiscal 2022 ended september 30, 2021.
RZLT Ratings Summary
RZLT Quant Ranking